Tyzavan (Vancomycin Injection, premixed)

Tyzavan is a branded intravenous formulation of vancomycin (a glycopeptide antibiotic) supplied as a ready-to-use premixed solution. Each Tyzavan bag is a single-dose flexible bag containing vancomycin at 5 mg/mL. For example, the 100 mL bag contains 500 mg vancomycin (100 mL × 5 mg/mL). Tyzavan is manufactured by Hikma Pharmaceuticals and is the only FDA-approved room-temperature-stable, premixed vancomycin solution on the U.S. market. It requires no reconstitution or dilution before use, allowing faster preparation in clinical settings.

• Dosage forms (strengths): Tyzavan is available in seven strengths (all at 5 mg/mL) to support flexible dosing: 500 mg/100 mL, 750 mg/150 mL, 1 g/200 mL, 1.25 g/250 mL, 1.5 g/300 mL, 1.75 g/350 mL, and 2 g/400 mL. Each is supplied as a sterile, single-dose infusion bag.
• Ready-to-use format: Because the bags are premixed, no compounding, thawing, or dilution is needed. This “ready-to-use” design can speed up administration (important in urgent infections) and reduce compounding errors. The bags meet USP <797> sterility standards and can be stocked in ADCs (automated dispensing cabinets) and code carts for rapid access.
• Stability and packaging: Tyzavan bags are stable at controlled room temperature (15–25 °C). According to the manufacturer, unopened Tyzavan has about a 16-month shelf life, and once the protective pouch is opened the solution should be used within 28 days. Storage instructions are to keep the bag in its overwrap until use, at room temperature (59–77 °F).

Indications

Tyzavan (vancomycin) is indicated for serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and other staphylococci. According to the official labeling, Tyzavan may be used (in patients ≥1 month old) for:

• Septicemia (bloodstream infection)
• Endocarditis (heart valve infection)
• Skin and skin-structure infections (e.g. cellulitis)
• Bone and joint infections (osteomyelitis, septic arthritis)
• Lower respiratory tract infections (e.g. pneumonia)

Tyzavan is intended for situations where adequate dosing (using the available bag strengths) can be achieved. Vancomycin should be used only for proven or strongly suspected Gram-positive infections to minimize resistance. Always confirm indications with current guidelines or an infectious disease specialist.

Administration and Dosing

• Route: Intravenous (IV) infusion only. Tyzavan is not for oral use (vancomycin has no oral absorption for systemic infection).
• Infusion rate: Infuse Tyzavan over at least 60 minutes. Rapid IV infusion of vancomycin can cause “infusion reactions” (e.g. red-man syndrome: flushing, rash, hypotension). To reduce this risk, always give the infusion slowly (≥60 min for typical doses). In practice, higher doses or smaller patients may warrant even longer infusion times.
• Dosage: Vancomycin dosing is weight- and renal-function based. As a general example (from the Tyzavan highlights section), a common regimen for adults with normal kidneys is about 2 g per day, given as either 500 mg every 6 hours or 1 g every 12 hours. In critically ill or severe infections (e.g. MRSA bacteremia), higher doses (up to 4–6 g/day) may be used under specialist guidance. Pediatric dosing also depends on weight and age. Always follow a prescriber or pharmacist’s instructions for exact dose and adjustments based on patient factors (especially kidney function).
• Handling: Remove the bag from its overpouch before use. Do not mix Tyzavan with other drugs or additives (no in-line mixing) as beyond-standard compatibilities. Inspect the solution for particulate matter or discoloration before use. Use aseptic technique when spiking the bag port. After starting the infusion, if any adverse reaction occurs (e.g. severe rash or hypotension), stop the infusion and treat appropriately.

Advantages of the Premixed Formulation

Tyzavan’s premixed format offers several practical benefits over traditional vancomycin vials:

• Convenience and Speed: No reconstitution or dilution is needed – each strength is already at the standard concentration (5 mg/mL). This saves pharmacy preparation time, removes a compounding step, and reduces the risk of calculation or dilution errors. It also enables faster antibiotic administration in emergencies.
• Sterility and Consistency: The drug is produced under cGMP standards in a sterile, controlled environment Using a sealed premix bag reduces opportunities for microbial contamination compared to manual compounding.
• Flexible Dosing: With seven available strengths, caregivers can choose the bag that most closely matches the ordered dose, minimizing leftover waste. For example, if a patient needs 1 g, one can use the 200 mL bag (1 g) rather than reconstituting two 500 mg vials.
• Room-Temperature Stability: Tyzavan does not require refrigeration for storage. It can be kept at room temperature (15–25 °C) with a long shelf life. This is more convenient than frozen or refrigerated premixes, and beneficial for stock in code carts or warm zones.
• Waste Reduction: Using premeasured bags reduces waste from unused drug or diluent. Tyzavan is single-dose (discard any unused portion), so there’s no leftover concentrate requiring disposal.

Storage and Handling

• Storage Conditions: Keep unopened Tyzavan bags in their original outer packaging at 15–25 °C (59–77 °F). Protect from light and freezing. The manufacturer indicates an unopened shelf life of about 16 months (check the expiration date on the carton).
• After Opening: Open the overwrapping just before use. Once removed from the aluminum overpouch, use the bag within 28 days. Do not refrigerate after opening the pouch. Do not freeze. Discard any unused solution in the bag at the end of administration (this is a single-dose container).
• Preparation: Use standard aseptic technique. Do not add other medications or solutions to the Tyzavan bag unless compatibility with vancomycin is confirmed. If an IV line is used for other drugs, flush thoroughly to avoid drug incompatibilities.

Safety and Precautions

Tyzavan has the same safety profile as other IV vancomycin formulations. Key warnings include:

• Hypersensitivity: Do not use Tyzavan in patients with known allergy to vancomycin. Allergic reactions (e.g. anaphylaxis) can occur. If signs of anaphylaxis or severe hypersensitivity appear, stop the infusion immediately.
• Infusion Reactions (“Red Man Syndrome”): Rapid infusion can cause flushing, itching, rash (especially of the face, neck, and upper body), hypotension, or even shock. To minimize this, always infuse over ≥60 minutes. If any infusion reaction occurs, slow or stop the infusion and treat symptoms (e.g. antihistamines, IV fluids). Co-administration of IV anesthetics can worsen these reactions; administer Tyzavan before anesthetics when possible.
• Nephrotoxicity: Vancomycin can damage kidneys, especially at high doses or when combined with other nephrotoxic drugs. Monitor renal function (serum creatinine, urine output) during therapy. Adjust dosing for renal impairment. Avoid concurrent use of other nephrotoxins if possible.
• Ototoxicity: Vancomycin has been associated with hearing loss, tinnitus or balance issues, particularly in patients with kidney impairment or those on high doses. It may be reversible or permanent. Audiology monitoring can be considered in long-term or high-dose therapy. If ototoxicity signs occur, discontinuation or dose adjustment may be needed.
• Thrombophlebitis: IV vancomycin can irritate veins. Ensure proper IV placement (preferably central line for large doses) and infusion technique. Rotate infusion sites if needed.
• Other Adverse Effects: Vancomycin can rarely cause blood dyscrasias (e.g. neutropenia, thrombocytopenia), severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), or “red skin syndrome”. It also alters normal gut flora, so be alert for Clostridioides difficile infection (severe diarrhea) during and after therapy.
• Use in Pregnancy/Lactation: Vancomycin crosses the placenta and is present in breast milk. It should be used in pregnancy only if clearly needed; discuss with an obstetrician. Breastfeeding patients should consult their doctor, as infants have not been studied extensively.

Always use the full prescription guidelines and standard hospital protocols (including dosing calculators, infusion pumps, and patient monitoring). Because this summary is general, follow the full Tyzavan prescribing information and institutional policies.